Steven Margossian

Steven Margossian, MD, PhD

Physician

Assistant Professor of Pediatrics, Harvard Medical School

    Contact: 617-632-4882
  • Fax: 617-632-2095

Medical Services

Specialties

  • Hematopoietic Stem Cell Transplantation

Departments

  • Hematology / Oncology
  • Medicine

Programs

  • Stem Cell Transplantation
To schedule an appointment: Call 617-632-4882

Experience and Education

Education

Undergraduate

Massachusetts Institute of Technology,

Cambridge, MA

Graduate School

University of Texas Southwestern Medical School at Dallas,

Dallas, TX

Medical School

University of Texas Southwestern Medical Center Medical School - University of Texas Southwestern Medical,

Dallas, TX

Pediatric Hematology/Oncology

Children's Hospital Boston/Dana-Farber Cancer Institute,

Boston, MA

Center Internship - Pediatrics

Babies and Children's Hospital, College of Physicians and Surgeons, Columbia University Medical Center,

New York, NY

Pediatrics

Babies and Children's Hospital, College of Physicians & Surgeons, Columbia University Medical Center,

New York, NY

Certifications

Publications

Publications powered by Harvard Catalyst Profiles
  1. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2017 Nov 10.
  2. Ozuah NW, Dahmoush HM, Grant FD, Lehmann LE, LaCasce AS, Billett AL, Margossian SP. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1).
  3. Shulman DS, Lee MA, Lehmann LE, Margossian SP. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. J Pediatr Hematol Oncol. 2016 Nov; 38(8):610-614.
  4. Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016 Jul; 22(7):1275-1283.
  5. Treister NS, London WB, Guo D, Malsch M, Verrill K, Brewer J, Margossian S, Duncan C. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. Photomed Laser Surg. 2016 Apr; 34(4):178-84.
  6. Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1013-23.
  7. Sandora TJ, Graham DA, Conway M, Dodson B, Potter-Bynoe G, Margossian SP. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. Am J Infect Control. 2014 May; 42(5):485-9.
  8. Rork JF, Margossian SP, Nambudiri VE, Huang JT. Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. J Pediatr Hematol Oncol. 2014 Apr; 36(3):224-7.
  9. Lizarraga SB, Margossian SP, Harris MH, Campagna DR, Han AP, Blevins S, Mudbhary R, Barker JE, Walsh CA, Fleming MD. Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors. Development. 2010 Jun; 137(11):1907-17.
  10. Ho GP, Margossian S, Taniguchi T, D'Andrea AD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol. 2006 Sep; 26(18):7005-15.
  11. Show all
  12. Park WH, Margossian S, Horwitz AA, Simons AM, D'Andrea AD, Parvin JD. Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem. 2005 Jun 24; 280(25):23593-8.
  13. Montes de Oca R, Andreassen PR, Margossian SP, Gregory RC, Taniguchi T, Wang X, Houghtaling S, Grompe M, D'Andrea AD. Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood. 2005 Feb 01; 105(3):1003-9.
  14. Thiagarajan RR, Roth SJ, Margossian S, Mackie AS, Neufeld EJ, Laussen PC, Forbess JM, Blume ED. Extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with cardiomyopathy and hemophilia A. Intensive Care Med. 2003 Jun; 29(6):985-8.
  15. Margossian SP, Butow RA. RNA turnover and the control of mitochondrial gene expression. Trends Biochem Sci. 1996 Oct; 21(10):392-6.
  16. Margossian SP, Li H, Zassenhaus HP, Butow RA. The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity. Cell. 1996 Jan 26; 84(2):199-209.
  17. Stepien PP, Margossian SP, Landsman D, Butow RA. The yeast nuclear gene suv3 affecting mitochondrial post-transcriptional processes encodes a putative ATP-dependent RNA helicase. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):6813-7.
To schedule an appointment: Call 617-632-4882

Locations

Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337

Close